Hyperdiluted Triamcinolone Injections for Nasal and Alar Contouring

Area of Science:

• Dermatology
• Plastic Surgery
• Aesthetic Medicine

Background:

• Increasing demand for minimally invasive nasal contour refinement without surgery or volume augmentation.
• Hyaluronic acid fillers offer contour alteration but add volume and carry vascular risks.
• Intralesional corticosteroids induce soft-tissue thinning, previously used for postoperative supratip fullness.

Purpose of the Study:

• To present a novel nonsurgical, nonfiller technique for nasal soft-tissue reduction.
• Utilizing hyperdiluted triamcinolone acetonide (TAC) microinjections for targeted nasal and alar fullness.
• Establishing a case-series protocol with standardized Global Aesthetic Improvement Scale (GAIS) reporting.

Main Methods:

• Twenty adult patients received a 10-point microinjection protocol with hyperdiluted TAC (approx. 1.3 mg/mL).
• 1.0 mL was administered per session, repeated every 3 weeks for five sessions.
• Cumulative TAC dose per patient was approximately 6.5 mg.

Main Results:

• Patient-reported outcomes were assessed using the Global Aesthetic Improvement Scale (GAIS) at final follow-up.
• The study provides a patient-level GAIS reporting framework for transparent outcome documentation.
• The technique aims for gradual, localized soft-tissue thinning via minimized corticosteroid exposure.

Conclusions:

• Hyperdiluted TAC microinjections represent a distinct approach from surgical rhinoplasty and filler-based methods.
• This technique offers a potential solution for patients seeking subtle nasal soft-tissue reduction.
• The described protocol and reporting framework facilitate reproducible and transparent results in nonsurgical rhinoplasty.